Myeloid neoplasm with rearrangement of PDGFRA, but with no significant eosinophilia: should we broaden the World Health Organization definition of the entity?
Department of Histopathology, Heart of England NHS Foundation Trust, Birmingham, UK. zbigniew.rudzki@heartofengland.nhs.uk
Zbigniew
Z
Rudzki
Louise
L
Giles
Nicholas C P
NC
Cross
Matthew
M
Lumley
D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D004802:Eosinophilia / Q000209:etiology; D006801:Humans; D008297:Male; D009196:Myeloproliferative Disorders / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D014944:World Health Organization; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics*
D015514:Oncogene Proteins, Fusion; D039221:mRNA Cleavage and Polyadenylation Factors; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha